Afalaza tab for the races. 100 pieces

Description

Composition
Active substance:
Antibodies to endothelial NO-synthase affinity purified – 0.006 g *
Antibodies to prostate-antigen affinity-purified – 0,006 g *.
* Applied to lactose monohydrate in a mixture of three aqueous-alcoholic active substance dilutions diluted respectively at 10012, 10030, 100200 times
Excipients:
Lactose monohydrate, microcrystalline cellulose, magnesium stearate.
Description:
Tablets ploskotsilindricheskoy shape, with the notch and chamfer, from white to almost white color. On the flat side coated with Valium inscription MATERIA MEDICA, on the other flat side applied AFALAZA inscription.
Product form:
Lozenges. 20 tablets in blisters of PVC film and aluminum foil. 5 the contour of cellular packaging together with instructions for medical application is placed in a pile of cardboard.
Contraindications
Increased individual sensitivity to the drug.
Indications
Benign prostatic hyperplasia.
Dizuricheskie disorder (in the complex therapy): frequent urge to urinate, difficulty in urinating, pain and discomfort in the perineal region.
Interaction with other drugs
Incompatibilities with other drugs has not yet been registered.
Overdose
When possible overdose dyspeptic symptoms caused by members of the formulation excipients.
pharmachologic effect
Pharmacological group:
Benign prostatic hyperplasia means of treatment.
Pharmacodynamics:
Experimentally and clinically shown that antibodies to prostate-specific antigen (PSA) affinity-purified modified functional activity of endogenous PSA altered in benign prostatic hyperplasia, which is accompanied by increased regulatory impact of the antigen on functional and metabolic processes in the prostate tissue have a pronounced anti-inflammatory and anti-edema act.
Antibodies to endothelial NO-synthase affinity purified help to increase blood flow velocity, including vessels in the penis and prostate; a protective effect with respect to the endothelium (reduces vascular reactivity, decreased vascular spasm and improve peripheral microcirculation). The combined use of components in the complex preparation Afalaza accompanied by a synergistic effect: antibodies to endothelial NO-synthase due endotelioprotektivnogo action and improve vascularization enhance antiproliferative and anti-inflammatory activity of antibodies to PSA. The synergistic effect is probably due also nonspecific amplification mechanisms of intracellular signal transduction dilutions of antibodies to endothelial NO-synthase.
Patients with BPH preparation when used for 12 months, can reduce prostate volume, improve urodynamics indices (reducing residual urine volume, increasing urine maximum speed), significant reduction of severity dizuricheskih disorders without affecting the level of PSA.
The drug helps to improve the quality of life of patients with benign prostatic hyperplasia (BPH).
Experimentally shown the presence of the drug and the expressed anti-edematous action. The drug contributes to the normalization of functional state of prostate and lower urinary tract, improvement of urodynamic parameters (reducing residual urine volume, increasing urine maximum speed), the normalization PSA.
Pharmacokinetics:
Sensitivity modern physico-chemical methods of analysis (gas-liquid chromatography, high performance liquid chromatography, gas chromatography-mass spectrometry) does not allow to evaluate the content of active components Afalaza drug in biological fluids, organs and tissues, making it impossible technically pharmacokinetics study.
Pregnancy and breast-feeding
Afalaza The drug is not intended for use in women.
Conditions of supply of pharmacies
Without recipe.
side effects
Possible reactions of individual hypersensitivity to the drug.
special instructions
The preparation includes lactose monohydrate, and therefore it is not recommended for patients with congenital galactosemia, malabsorption syndrome or glucose in congenital lactase deficiency.
Effect on the ability to drive
Afalaza does not affect the ability to drive vehicles and other potentially dangerous machinery.
Storage conditions
In the dark place at a temperature not higher than 25 ° C.
Keep out of the reach of children.
Dosing and Administration
Inside. 2 tablets 2 times a day, morning and evening (kept in the mouth until complete dissolution – without meals).
When dizuricheskih disorders recommended to take the drug for 16 weeks.
On doctor’s advice when the severity of pain and dizuricheskih violations in the first 2-3 weeks of therapy shows the drug up to 4 times per day.
To prevent the growth of the prostate in patients with benign prostatic hyperplasia and reduce the risk of disease progression, patients are advised to take the drug 2 times a day, morning and evening, for 12 months.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist